The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Is The Market Value Of The End Stage Renal Disease (ESRD) Drug Market Projected To Expand During 2026–2030?
The end stage renal disease (esrd) drug market size has seen substantial growth recently. It is anticipated to expand from $148.55 billion in 2025 to $171.12 billion in 2026, at a compound annual growth rate (CAGR) of 15.2%. This historical growth can be attributed to the rising prevalence of CKD, increased awareness of ESRD, a surge in dialysis centers, advancements in renal therapeutics, and government healthcare initiatives.
The end stage renal disease (esrd) drug market size is projected to experience substantial expansion in the coming years. It will grow to $304.07 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. This anticipated growth over the forecast period is primarily driven by advancements such as the development of precision medicine, the increasing availability of homecare dialysis, the incorporation of AI into patient monitoring, escalating investments in ESRD research and development, and the rising uptake of combination therapies. Furthermore, significant trends for the forecast period comprise personalized ESRD drug therapies, the provision of home-based dialysis options, the integration of telemedicine in chronic kidney disease management, sophisticated drug formulations addressing secondary complications, and an increasing embrace of combination therapeutic approaches.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
Which Core Factors Are Supporting The Expansion Of The End Stage Renal Disease (ESRD) Drug Market?
The increasing prevalence of obesity and diabetes is anticipated to fuel the expansion of the end-stage renal disease (ESRD) drug market. Obesity is characterized by an excessive or abnormal accumulation of fat that poses health risks. Conversely, diabetes is a chronic condition where the pancreas either fails to produce sufficient insulin or the body is unable to effectively use the insulin it produces. For individuals with renal disease, effective management of fluid and electrolyte balance, blood pressure, and removal of waste products through dialysis can lead to overall health improvements, potentially resulting in weight loss and better blood sugar regulation. Illustrating this trend, in 2023, the World Obesity Federation, a non profit membership organization, predicted that by 2035, the annual economic burden of overweight and obesity would amount to US$ 4.32 trillion, representing almost 3% of the global economy. Furthermore, in June 2024, data from the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition where blood sugar levels are elevated but not high enough for a diabetes diagnosis) in 2023, marking an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the growing number of obesity and diabetes cases is set to boost the market for end-stage renal disease (ESRD) drugs.
How Is The End Stage Renal Disease (ESRD) Drug Market Structured Across Different Market Segments?
The end stage renal disease (esrd) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
What Trends Are Driving Changes In The End Stage Renal Disease (ESRD) Drug Market?
Leading companies within the end-stage renal disease (ESRD) drug market are concentrating on product authorizations, such as Jardiance, to enhance their market revenues. Empagliflozin is a medication designed to aid individuals with type 2 diabetes and to reduce the probability of cardiovascular problems in persons with type 2 diabetes who also suffer from heart failure or cardiovascular disease. For example, in September 2023, Boehringer Ingelheim Pharmaceuticals Inc., a US-based pharmaceutical entity, obtained FDA approval for Jardiance. Jardiance has been sanctioned for multiple indications, including diminishing the risk of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease who are at risk of progression. It also lowers the risk of a sustained decrease in estimated glomerular filtration rate (eGFR) in adults with heart failure. Jardiance functions as a sodium-glucose cotransporter 2 (SGLT2) inhibitor and should not be administered to patients with type 1 diabetes or those with an eGFR below 20 ml/min/1.73 m.
Who Are The Companies Shaping The End Stage Renal Disease (ESRD) Drug Market Landscape?
Major companies operating in the end stage renal disease (esrd) drug market are Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA
Access The Complete End Stage Renal Disease (ESRD) Drug Market Report:
Which Region Contributes The Most To The End Stage Renal Disease (ESRD) Drug Market?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2025. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access End Stage Renal Disease (ESRD) Drug Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
Browse Through More Reports Similar to the Global End Stage Renal Disease (ESRD) Drug Market 2026, By The Business Research Company
End Stage Renal Disease Esrd Drug Market Report 2026
Late Stage Chronic Kidney Disease Drugs Market Report 2026
Kidney Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model